Molecular Characteristics of Phlegm-heat Syndrome in Ischemic Stroke
ConditionIschemic Stroke, Acute
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorDongzhimen Hospital, Beijing
About this trial
The molecular characteristics of ischemic stroke with phlegm-heat syndrome and candidate biomarkers were identified based on multi-omics data. The main purpose of this study is to validate the molecular characteristics and biomarkers of phlegm-heat syndrome in ischemic stroke, and to demonstrate the association of biomarkers with clinical outcomes.
Eligibility criteria
Qualifiers
Acute ischemic stroke.
Symptom onset within 72 hours.
Diagnosis of phlegm-heat syndrome or non-phlegm-heat syndrome.
Male or female ≥18 years and ≤ 80 years.
Disqualifiers
Acute infectious diseases or acute exacerbations of chronic diseases within one month before enrollment.
Patients has previous stroke.
Other conditions that lead to motor dysfunction (e.g., severe osteoarthritis, rheumatoid arthritis).
Renal or hepatic insufficiency, tumors, immune diseases, severe underlying diseases.
Trial design
Treatments tested in this trial
- Guideline-based treatment
Treatment groups
84 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov